RxDoctor Payments Data

Karl Torgerson

Physician Assistant · Enterprise, UTNPI 1417253824

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $6,633 of the $7,855 with a category attached, or 84.4%. It is spread thinly across 47 manufacturers, the largest accounting for just 16.4% — the pattern of someone who eats at a lot of different presentations. Among physician assistant clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,855in general payments, 2019–2025

Across 396 payments — averaging $19.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Biohaven Pharmaceuticals, Inc.$1K
  • AstraZeneca$550
  • Novartis$530
  • Pfizer$457
  • Amgen$419
  • plus $3K from 41 others

What the payments were for

  • Consulting fees$80010%
  • Travel & lodging$1382%
  • Food & beverage$6,63384%
  • Education$2844%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,855 in reported general payments places this provider in the 95th percentile of 1,543 physician assistant providers in Utah.

See all physician assistant providers in Utah

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide114$118,178
OzempicSemaglutide80$102,218
JardianceEmpagliflozin97$101,987
EliquisApixaban107$101,678
MyrbetriqMirabegron56$53,441
TrulicityDulaglutide32$52,466
RybelsusSemaglutide25$48,866
FarxigaDapagliflozin Propanediol27$41,353
Repatha SureclickEvolocumab53$34,523
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog22$34,028
ZenpepLipase/Protease/Amylase19$33,045
MovantikNaloxegol Oxalate42$25,156
EntrestoSacubitril/Valsartan16$25,154
XareltoRivaroxaban11$19,139
LinzessLinaclotide28$18,329

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$365$170,644146 claims
Novo NordiskOzempic, Rybelsus$327$151,084105 claims
PfizerEliquis, Premarin$457$103,894118 claims
Boehringer IngelheimJardiance$313$101,98797 claims
Astellas Pharma US IncMyrbetriq$284$53,44156 claims
AstraZenecaFarxiga$550$41,35327 claims
Aimmune Therapeutics, Inc.Zenpep$108$33,04519 claims
NovartisEntresto$530$25,15416 claims
Johnson & JohnsonXarelto$66$19,13911 claims
AbbVieLinzess$1,286$18,32928 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$59$12,88919 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$143$11,33311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,543 physician assistant providers in Utah.

Other physician assistant in Enterprise

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →